Pramparo, Tiziano http://orcid.org/0000-0001-6929-1027
Steiner, Robert D.
Rodems, Steve
Jenkinson, Celia
Funding for this research was provided by:
Travere Therapeutics, Inc. (Travere Therapeutics, Inc.)
Article History
Received: 8 August 2022
Accepted: 20 November 2022
First Online: 17 January 2023
Declarations
:
: Not applicable.
: Not applicable.
: TP, SR, CJ are full-time employees of Travere Therapeutics, Inc., and may have an equity or other financial interest in Travere Therapeutics, Inc. RDS is an employee of PreventionGenetics, an Exact Sciences company. He has equity interest in and has received consulting fees from Acer Therapeutics and PTC Therapeutics. He has received consulting fees from Aeglea BioTherapeutics; Alexion Pharmaceuticals, Inc; Best Doctors; Health Advances LLC; Leadiant, Precision for Value; and Travere Therapeutics, Inc; and honoraria from Medscape/WebMD and The France Foundation. He received no funding to support writing and revising this manuscript. He has received research funding from Alexion Pharmaceuticals, Inc and the Smith Lemli Opitz Foundation.